The effects of TNF blockade (using etanercept) on substrates of mood and cognition in patients with inflammatory arthritis.

Trial Profile

The effects of TNF blockade (using etanercept) on substrates of mood and cognition in patients with inflammatory arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Acronyms SPECT
  • Most Recent Events

    • 08 Oct 2014 Accrual to date is 86% according to United Kingdom Clinical Research Network record
    • 08 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network .
    • 21 Jun 2012 United Kingdom Clinical Research Network reports accrual to date changed from 83% to 86%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top